Spruce Biosciences (SPRB) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
9 Nov, 2026Executive summary
Q3 2026 net loss widened to $24.0m from $8.2m a year earlier, driven by higher TA-ERT development and manufacturing spending.
TA-ERT BLA submission for MPS IIIB remains on track for December 2026, seeking accelerated approval based on CSF HS-NRE reduction as a reasonably likely surrogate endpoint.
CRHX-101 assets and liabilities were transferred to Adrenyx in November; a pro rata shareholder distribution is planned for H1 2027, subject to conditions.
Financial highlights
Q3 operating expenses were $24.0m vs. $8.2m YoY; R&D was $18.1m vs. $5.0m and G&A was $5.8m vs. $3.2m.
9M operating expenses were $52.5m vs. $25.4m; R&D was $37.9m vs. $15.4m and G&A was $14.6m vs. $10.0m.
9M net loss was $52.5m vs. $24.3m, or $23.71 vs. $41.25 per share; Q3 loss per share was $8.51 vs. $14.58.
9M operating cash use was $44.6m vs. $26.9m; financing provided $83.5m, primarily from the April offering, August private placement and Avenue loans.
Outlook and guidance
TA-ERT BLA submission seeking accelerated approval is anticipated in December 2026; potential U.S. commercial launch is in 2027 if approved.
Second TA-ERT PPQ batch and Transform confirmatory study are expected to begin in December 2026; the first PPQ batch, completed in July, is planned for the BLA.
Transform is expected to enroll ~14 children ages 1–5 with severe MPS IIIB; the U.S. open-label EAP began in November and is expected to enroll ~10 children.
Cash of $87.7m was expected to fund planned operations and debt obligations into 2H 2027; separately, the filing cited insufficient funding for 12 months absent alternative financing and substantial doubt about going concern.
R&D spending is expected to rise as TA-ERT advances through BLA review, the confirmatory study and potential approval; commercial and manufacturing capabilities are also planned to expand.
Latest events from Spruce Biosciences
- December BLA plan pairs a biomarker-led accelerated-approval case with an initiated confirmatory trial.SPRB
3rd Annual Guggenheim Healthcare Innovation Conference - Lead therapy for MPS IIIB shows strong efficacy, with BLA submission and global launch planned.SPRB
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 net loss was $16.2M as R&D spending surged, with $96.3M in cash and new leadership.SPRB
Q2 2026 - Lead therapy for MPS IIIB nears approval, showing strong efficacy and commercial readiness.SPRB
Jefferies Global Healthcare Conference 2026 - Directors elected, all proposals approved, and strategic plans funded for regulatory milestones.SPRB
AGM 2026 - TA-ERT advances toward BLA submission as finances and leadership strengthen.SPRB
Q1 2026 - Annual meeting to elect directors, ratify auditor, and vote on executive pay and its frequency.SPRB
Proxy filing - Proxy covers director elections, auditor ratification, executive pay, and governance after a 1:75 reverse split.SPRB
Proxy filing - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 2026